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p27 mediates Cdk2 inhibition and is also found in cyclin D1-Cdk4 complexes. The present data support a
role for p27 in the assembly of D-type cyclin-Cdk complexes and indicate that both cyclin D1-Cdk4-p27
assembly and kinase activation are regulated by p27 phosphorylation. Prior work showed that p27 can be
phosphorylated by protein kinase B/Akt (PKB/Akt) at T157 and T198. Here we show that PKB activation and
the appearance of p27pT157 and p27pT198 precede p27-cyclin D1-Cdk4 assembly in early G1. PI3K/PKB
inhibition rapidly reduced p27pT157 and p27pT198 and dissociated cellular p27-cyclin D1-Cdk4. Mutant p27
allele products lacking phosphorylation at T157 and T198 bound poorly to cellular cyclin D1 and Cdk4.
Cellular p27pT157 and p27pT198 coprecipitated with Cdk4 but were not detected in Cdk2 complexes. The
addition of p27 to recombinant cyclin D1 and Cdk4 led to cyclin D1-Cdk4-p27 complex formation in vitro. p27
phosphorylation by PKB increased p27-cyclin D1-Cdk4 assembly in vitro but yielded inactive Cdk4. In
contrast, Src pretreatment of p27 did not affect p27-cyclin D1-Cdk4 complex formation. However, Src treat-
ment led to tyrosine phosphorylation of p27 and catalytic activation of assembled cyclin D1-Cdk4-p27 com-
plexes. Thus, while PKB-dependent p27 phosphorylation appears to increase cyclin D1-Cdk4-p27 assembly or
stabilize these complexes in vitro, cyclin D1-Cdk4-p27 activation requires the tyrosine phosphorylation of p27.
Constitutive activation of PKB and Abl or Src family kinases in cancers would drive p27 phosphorylation,
increase cyclin D1-Cdk4 assembly and activation, and reduce the cyclin E-Cdk2 inhibitory function of p27.
Combined therapy with both Src and PI3K/PKB inhibitors may reverse this process.
Progression through the G1 phase of the cell division cycle is
rate limiting for mammalian cell proliferation and is driven by
the sequential formation and activation of D-type cyclin-Cdk4
and Cdk6 complexes, followed by cyclin E-Cdk2 activation
(53). The inhibitor of Cdk4 proteins binds Cdk4 and Cdk6,
leading to the loss of cyclin binding (54). The kinase inhibitor
protein (KIP) family members, p21, p27, and p57, bind and
inhibit cyclin E-bound Cdk2. p27 is expressed ubiquitously and
importantly regulates G1 progression. While p27 was initially
identified as a Cdk2 inhibitor (29, 48, 57), it also appears to
promote the assembly of p27-cyclin D1-Cdk4 and Cdk6 com-
plexes in vitro (32) and/or the stabilization of these complexes
in cells (3, 12, 32). Mechanisms regulating the putative assem-
bly function of p27 have remained largely unknown.
Cyclin D1 accumulation in early G1 results from mitogen-
mediated increases in its transcription, translation, and protein
stabilization (16, 43). Cyclin D1 is unstable in G0 (3, 46), and
newly synthesized cellular cyclin D1 does not appreciably as-
semble into cyclin D1-Cdk4 complexes in quiescent cells (12).
Cyclin D1-Cdk4 assembly is growth factor dependent since
exogenously overexpressed cyclin D1 cannot form complexes
with Cdk4 in serum-starved fibroblasts, but it does so readily in
cells grown in complete medium (40). Cyclin D1-Cdk-KIP as-
sembly is associated with cyclin D1 stabilization (2, 9, 32). In
mouse embryonic fibroblasts lacking both p21 and p27, D-type
cyclins are rapidly degraded, and cyclin D1-Cdk complexes,
while present, are barely detectable. Reintroducing p27 or p21
into these mouse embryonic fibroblasts reversed the acceler-
ated cyclin D1 proteolysis and led to the appearance of stable
cyclin D-Cdk4 complexes (2, 9).
In addition to contributing to D-type cyclin stabilization, the
assembly of p27-cyclin D-Cdk complexes would contribute to
G1-to-S progression via at least two other mechanisms. First,
cyclin D1, Cdk4, and Cdk6 lack nuclear localization signals.
LaBaer et al. provided evidence that p21 and/or p27 could
facilitate nuclear import of the assembled complexes (32). Sec-
ond, a shift in the p27 binding equilibrium toward cyclin D-
Cdks could potentiate cyclin E-Cdk2 activation. Posttransla-
tional events that promote p27 binding to cyclin D-Cdks in
early G1 may reduce p27 availability to cyclin E-Cdk2, contrib-
uting to cyclin E-Cdk2 activation (47). These events character-
ize the restriction point in late G1 when cell cycle progression
becomes mitogen independent and resistant to G1 arrest by
inhibitory cytokines, such as transforming growth factor 
(TGF-) (6, 33).
Prior work indicates that protein kinase B (PKB) can phos-
phorylate p27 and contributes to the regulation of cellular p27
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(38, 55, 59). TGF--resistant human mammary epithelial cells
(HMEC) showed elevated PKB activity, and transfection of
constitutively active PKB conferred TGF- resistance to sen-
sitive cells (38) and increased p27-cyclin D1-Cdk4 complexes
and activity (12). We and others showed that PKB phosphor-
ylates p27 at threonine 157 (T157) (38, 55, 59), and PKB was
also shown to phosphorylate p27 at T198 in vitro (19, 42).
SGK1 also appears to phosphorylate p27 in a PDK1- and
mTOR-dependent manner (24). While both Ras and PKB
overexpression increase p21- and p27-bound cyclin D-Cdk
complexes (12, 35, 50), the relationship between PKB action
on p27 phosphorylation sites and the potential for p27 to
promote cyclin D-Cdk assembly has not been elucidated.
In the present study, we show that cellular PKB activation
and the appearance of p27pT157, p27pT198, and p27-cyclin
D1-Cdk4 complexes have similar kinetics in early G1. PI3K/
PKB inhibition causes p27-cyclin D1-Cdk4 dissociation. Cellu-
lar Cdk4-bound p27 is more phosphorylated at T157 and T198
than Cdk2-bound p27 in vivo, and transfected p27T157A and
p27T198A show reduced binding to cellular cyclin D1 and
Cdk4 compared to that of p27WT. PKB phosphorylates p27 in
a T157- and T198-dependent manner and increases p27-cyclin
D1-Cdk4 assembly, but this does not yield active Cdk4 com-
plexes in vitro. Activation of the assembled p27-cyclin D1-
Cdk4 complex appears to require the tyrosine phosphorylation
of p27 that can be stimulated by Src treatment. These data
support a model in which PKB-mediated p27 phosphorylation
promotes the assembly of p27-cyclin D1-Cdk4 assembly in G1,
while action of other kinases, including Src, would permit the
tyrosine phosphorylation of p27 and cyclin D-Cdk activation.
MATERIALS AND METHODS
Cell culture. MCF-7 cells were grown in improved Eagle’s medium (8), and the
WM35 melanoma line was cultured in RPMI 1640 medium as described previ-
ously (8, 13, 23). WM35 cells were arrested by serum starvation (0.1% fetal
bovine serum) for 48 h. Cell cycle entry was stimulated by the addition of 5%
fetal bovine serum, and cells were recovered at intervals for protein and cell cycle
assays. The finite life span HMEC strain 184 was cultured as described previously
(58) and synchronized in G0 by deprivation of epidermal growth factor (EGF)
receptor signaling for 48 h (51). Cell cycle reentry was stimulated by the addition
of complete medium containing EGF.
Plasmids, site-directed mutagenesis, and transfections. Mammalian expres-
sion vectors YFPp27WT and YFPp27T157A were described previously (38).
YFPT198A and YFPp27T157A/T198A were generated using the QuikChange
site-directed mutagenesis kit (Stratagene). Mutations were confirmed by DNA
sequencing. Five micrograms of each vector was transfected into asynchronous
MCF-7 cells using Lipofectamine Plus (Gibco) according to the manufacturer’s
instructions. His-tagged p27WT, p27S10A, p27T157A, p27T198A, p27T157A/
T198A, and p27S10A/T157A/T198A vectors were generated by site-directed
mutagenesis of the pET28b His-p27WT. Mutations were confirmed by DNA
sequencing.
Flow cytometry. Cells were pulse labeled with 10 mM of bromodeoxyuridine
(BrdU) for 2 hours and processed for flow cytometry as described previously
(51).
Antibodies. The anti-EGF receptor monoclonal antibody mAb225 was pro-
vided by Steve Wiley (University of Utah Medical Center, Salt Lake City, UT).
Antibodies to phospho-PKB (Ser473), total PKB, phospho–mitogen-activated
protein kinase (MAPK), and total MAPK were obtained from Cell Signaling;
antibodies to Cdk4 (C-22), p27 (C-19), phospho-p27 (T187), phospho-p27 (S10),
and Cdk2 (M-2) were from Santa Cruz Biotechnology; antibody to p27 was from
Transduction Laboratories; antibodies to phospho-p27 (T157) and phospho-p27
(T198) were from R&D Systems; antibodies to cyclin D1 (DCS-6 and Ab-3) and
Cdk4 (DCS-35 and Ab-4) were from Lab Vision (Neomarkers); and antibody to
-actin was obtained from Sigma. Cyclin E1 antibody (E12) was obtained from
E. Harlow.
Immunoprecipitation and Western blotting. Cell lysis, immunoprecipitation,
and immunoblotting were performed as described previously (51). Immunopre-
cipitation and immunoblotting experiments used 200 g and 50 g of protein
lysates, respectively, unless otherwise indicated. All proteins precipitated in im-
munoprecipitation-Western blotting have been shown not to bind to nonspecific
antibody controls. Controls with antibody alone were run alongside all immuno-
precipitates, and equal protein loading of all Western blots was verified by
blotting for -actin.
Recombinant proteins and purification. Recombinant His-tagged p27WT,
p27S10A, p27T157A, p27T198A, p27T157A/T198A, and p27S10A/T157A/
T198A were transformed into Escherichia coli BL21(DE3) cells grown in Terrific
Broth medium (Difco) to the mid-exponential phase and induced with 1 mM
isopropyl--D-thiogalactopyranoside for 3 h at 37°C. Cells were harvested and
lysed using the BugBuster protein extraction reagent (Novagen), following the
manufacturer’s protocol. The soluble fraction was then applied to a 5-ml HisTrap
nickel-nitrilotriacetic acid column (Amersham), washed with 10 column volumes
of buffer I (50 mM Tris, 233 mM NaCl, 20 mM imidazole, 5% glycerol, pH 8.3)
and eluted with linear imidazole gradient in buffer II (50 mM Tris, 233 mM
NaCl, 500 mM imidazole, 5% glycerol, pH 8.3). Fractions containing His-p27
proteins were pooled and concentrated to about 5 mg/ml.
Baculoviral supernatant for recombinant Flag-cyclin D1 and His-Cdk4 were
kindly provided by Alan Diehl. Flag-cyclin D1 was harvested from infected Sf-9
cells, and protein was purified using anti-Flag M2 affinity gel (Sigma). Protein
was eluted by competitive elution using Flag peptide (Sigma). Recombinant
His-Cdk4 was also harvested from infected Sf-9 cells, and protein was purified
using a 5-ml HisTrap nickel-nitrilotriacetic acid column as described above for
recombinant His-p27. Cyclin D-Cdk4 assembly assays were carried out using
either purified cyclin D1 and Cdk4 or crude baculovirus lysate (see below).
PKB kinase assays. Recombinant active PKB was obtained from Upstate and
Cell Signaling. Reaction conditions (time and PKB concentrations of 20 to 200
ng) were varied to determine the linear range of kinase assay conditions. For the
quantitative kinase reactions, 100 ng of PKB (Upstate) or 25 ng of PKB (Cell
Signaling) was incubated with 5 g of recombinant His-p27 (His-p27WT, -S10A,
-T157A, -T198A, -T157A/T198A, or -S10A/T157A/T198A) in 20 l of kinase
reaction buffer (20 mM HEPES, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM
dithiothreitol, 100 M ATP). Reactions were carried out at 30°C for 15 min in
the presence of 10 Ci [-32P]ATP, products were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and incorporated radioactivity was
quantified by phosphorimager.
To test the action of cellular PKB on p27 in vitro, activated PKB was immu-
noprecipitated with PKBpS473 antibody from increasing amounts of asynchro-
nous WM239 cell lysate and reacted with His-p27 proteins as described above.
The WM239 cell line has no PTEN and has high levels of activated cellular PKB
(38). Amounts of immunoprecipitated PKB and substrate and reaction duration
were adjusted to ensure that reactions were in the linear range. Immunoprecipi-
tated PKB was reacted with 5 g of recombinant p27-His as described above.
Assembly of cyclin D1, Cdk4, and p27 complexes. To assay cyclin D1 and Cdk4
assembly, baculovirus-expressed human Flag-tagged cyclin D1 and His-tagged
Cdk4 were purified as described above and then incubated in assembly buffer (20
mM HEPES, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM dithiothreitol) at 25°C
for 20 min in the presence or absence of 100 ng His-p27. The reactions were then
diluted with 500 ml of ice-cold Nonidet P-40 lysis buffer (0.5% NP-40, 50 mM
Tris, pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 0.02 mg
each of aprotinin, leupeptin, and pepstatin per ml) (51) for immunoprecipitation
with a cyclin D1 antibody (Ab-3) or a Cdk4 antibody (DCS-35), followed by
immunoblotting for cyclin D1, Cdk4, and p27. Assembly reactions using crude
baculovirus lysate as the source for cyclin D1 and Cdk4 yielded similar results to
those carried out with purified proteins.
To assay the effect of PKB and/or Src on the assembly function of p27, His-p27
proteins were reacted with immunoprecipitated cellular PKB as described above or
with recombinant Src using kinase assay conditions described previously (10). Re-
action products were boiled to denature and precipitate PKB and/or Src, and heat-
stable p27 was recovered from the supernatant following centrifugation and assayed
for the ability to assemble purified recombinant cyclin D1 and Cdk4 as described
above. To test the effect of Src on PKB-treated p27 in p27-cyclin D-Cdk4 assembly,
p27 was treated with PKB as described above and boiled, and heat-soluble p27 was
recovered from the supernatant and mixed with cyclin D1 and Cdk4 for 30 min
under the assembly conditions described above. Src kinase was then added for a
further 15 min prior to the addition of Cdk4 antibody, assembled complexes were
resolved, and associated proteins were detected by immunoblotting.
To compare the abilities of cellular p27 isolated from different cyclin-Cdk
complexes to promote the assembly of recombinant cyclin D1 and Cdk4 in vitro,
immunoprecipitation of either cellular cyclin D1 or Cdk2 was performed using
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appropriate antibodies, and the heat-stable cellular p27 was released from the
immunoprecipitates by boiling in assembly buffer. Recovered p27 was titrated to
ensure that equivalent p27 amounts were added to reaction mixtures, and their
abilities to assemble recombinant cyclin D1-Cdk4 were then assayed as described
above.
Activity of the p27-cyclin D1-Cdk4 complex. His-p27 was treated with PKB, Src,
or both as described above and then isolated by boiling. The isolated p27 was then
used in assembly assays with purified recombinant cyclin D1 and Cdk4 as described
above. The assembled p27-cyclin D1-Cdk4 complexes were precipitated with anti-
Cdk4 antibody, and cyclin D1-Cdk4 kinase activity was assayed using recombinant
pRb as the substrate as described previously (51). Cdk4 immune complexes were
washed and reacted with 3 g recombinant pRb in kinase reaction buffer (50 mM
HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2). Reactions were carried out at 30°C
for 20 min in the presence of 10 Ci [-32P]ATP, products were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and incorporated radioactivity
was quantified by a phosphorimager.
RESULTS
PKB activation and p27-cyclin D1-Cdk4 complexes increase
in G1. PKB activation is required for G1 cell cycle progression
(37). To assay the temporal relationship between PKB activa-
tion and p27-cyclin D1-Cdk4 assembly, HMEC strain 184 cells
were synchronized in G0 by EGF depletion and then released
by repletion of EGF (Fig. 1A). In addition, the human mela-
noma line WM35 was serum starved, and then cell cycle reen-
try was stimulated by the addition of 5% serum (Fig. 1B).
HMEC and WM35 cells were recovered at intervals for cell
cycle distribution analysis by flow cytometry and for protein
analysis. The percent S phase is indicated for each time point
(Fig. 1A and B). The total PKB levels showed little variation in
HMEC and a subtle increase in mid-G1 in WM35. Levels of
activated Ser 473-phosphorylated PKB (PKBpS473) were min-
imal in G0, increased within 1 h of G0 release, and peaked at
3 h in both cell types. PKBpS473 remained elevated during G1
and declined as cells entered the S phase. The kinetics of PKB
activation were similar in cells released from contact inhibition
(data not shown).
p27 protein was maximal in G0 and declined with S phase
FIG. 1. PKB activation precedes cyclin D1-Cdk4-p27 assembly in G1. (A) HMEC 184 cells were G0 arrested by EGF deprivation and released
by the addition of EGF at time zero. At intervals thereafter, cells were collected for BrdU labeling, flow cytometry, and protein analysis. Protein
levels were detected by Western blotting. Left panel, cell cycle entry is indicated by S%; right panel, Cdk4 complexes were immunoprecipitated
and resolved, and associated proteins were detected by immunoblotting. (B) WM35 cells were G0 arrested by serum deprivation and released by
the addition of full serum at time zero. Cells were collected as described above. Cdk4 complexes were immunoprecipitated, and associated proteins
were detected by immunoblotting (right panel). (C) p27 phosphorylated at S10, T198, T157, or T187 was detected using phospho-specific
antibodies. “Ab only” indicates reaction of precipitating antibody with protein A-Sepharose without lysate to control for reactivity of immuno-
blotting antibody with heavy or light chain of the antibody used in immunoprecipitation (IP). FBS, fetal bovine serum; NR-IgG, normal rabbit
immunoglobulin G.
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entry as described previously (51). Levels of p27 phosphory-
lated at either S10, T157, T198, or T187 were detected using
phospho-specific antibodies (Fig. 1C). In WM35 cells, p27S10
was maximally phosphorylated in G0 and fell rapidly in early
G1, during the same time that PKB activation increased. While
total p27 levels fell during this interval, the detection of
p27pT198 increased over 1 to 3 h after release from quiescence
and remained detectable for several hours thereafter.
p27pT157 was minimal in G0 and rising in early G1 with a peak
at 6 h. Both p27pT157 and p27pT198 decreased as cells moved
into the S phase. As expected, the T187 phosphorylation of p27
was only minimally detected until late G1 (52, 60), coincident
with peak cyclin E-Cdk2 activation (18).
p27-cyclin D1-Cdk4 complexes increased during early G1
despite the concurrent reduction of total p27 protein levels and
was temporally associated with PKB activation and the appear-
ance of both p27pT157 and p27pT198. The increase in p27-
cyclin D1-Cdk4 complexes preceded the rise in total cyclin D1
levels in both lines, more notably in HMEC, where S phase
entry was slower than in WM35 (Fig. 1A and B), consistent
with the notion that Cdk binding stabilizes cyclin D1 (32, 46).
PI3K/PKB inhibition causes p27-cyclin D1-Cdk4 dissocia-
tion. Sustained inhibition of the PI3K/PKB pathway with re-
sultant G0 arrest has been shown to reduce cyclin D1 and
increase p27 (38, 62). To test the effects of short-term PI3K
inhibition on p27 complexes, p27 was immunoprecipitated
from proliferating MCF-7 cells before and at intervals after the
addition of 10 M LY294002. While 6 h of PI3K inhibition did
not affect levels of PKB, cyclin D1, Cdk4, Cdk2, cyclin E2, or
p27, the drug rapidly reduced levels of PKBpS473, p27pT157,
p27pT198, and p27-cyclin D1-Cdk4 complexes (Fig. 2A). The
loss of Cdk4 from p27 complexes was slower than that ob-
served for cyclin D1 at 6 h (Fig. 2A) but was appreciable within
6 h and fell further within 24 h of PI3K/PKB inhibition (Fig.
2D). p27 association with cyclin E1 and Cdk2 increased pro-
gressively during 6 h of LY294002 treatment. The loss of p27-
bound cyclin D1 and Cdk4 following PI3K/PKB inactivation
was notable within 6 h of PI3K/PKB inhibition and preceded
G1 arrest. Cells took 24 h to undergo full G1 arrest (Fig. 2B).
LY294002 inhibits PI3K and PKB within minutes. To test
the effects of LY294002 on p27 over a more rapid time course,
cells were recovered within 15 min and at intervals over a
4-hour period. p27pT157 and p27pT198 levels fell within 15
min of LY294002 addition, while total p27 was unchanged. It is
noteworthy that p27pS10 and p27pT187 were unchanged over
6 h of PI3K/PKB inhibition (data shown are results for 0 to 4 h
in Fig. 2C).
In contrast to the effects of LY294002, MEK inhibition by 5
M U0126 for 24 h did not cause p27-cyclin D1-Cdk4 disso-
ciation (Fig. 2D). Inhibition of PKB and MAPK is shown by
diminished PKBpS473 and pMAPK, respectively (Fig. 2D).
p27S10A, p27T157A, and p27T198A show reduced phosphor-
ylation by PKB in vitro. PKB has been reported to phosphor-
ylate p27 at T157, T198, and S10 in vitro. To test how phos-
phorylation at one site may influence phosphorylation at the
others, recombinant His-tagged p27WT, p27S10A, p27T157A,
p27T198A, p27T157D, p27T198D, p27T157A/T198A, and
p27S10A/T157A/T198A (p27AAA) were each used as sub-
strates in PKB kinase assays (Fig. 3A). For data shown, cellular
PKBpS473 was immunoprecipitated from WM239 asynchro-
nous cell lysates. All experiments were repeated using recom-
binant PKB from two different commercial sources, and effects
on p27 phosphorylation were confirmed. While the loss of the
potential to phosphorylate p27 at T157 reduced PKB-mediated
phosphorylation by approximately 50%, mutation converting
T198 to alanine reduced p27 phosphorylation by over 50%,
suggesting that phosphorylation at T198 influences that at
T157. As was observed for p27T198A, mutation converting S10
to alanine also reduced p27 phosphorylation by PKB by 80%,
suggesting that the conformation of p27S10 influences the po-
tential for p27 phosphorylation at other sites. While the PKB
phosphorylation of p27T157A/T198A was similar to that of
p27T198A, p27AAA was not phosphorylated by PKB in vitro
compared to mock reactions lacking PKB. The p27T157D and
p27T198D mutants showed the same loss of phosphorylation
by PKB, as did their respective alanine mutants. Thus, they did
not appear to function as phospho-mimetic in PKB kinase
assays (not shown).
The reduced action of recombinant PKB on p27S10A ob-
served by us and others (19, 44) could indicate that this site is
phosphorylated by PKB in vitro, or that the conformation of
S10 is important for PKB action at other sites (e.g., T157 and
T198). In WM35 cells, detection of p27pS10 is maximal in G0
and early G1 prior to PKB activation (Fig. 1B and C). To
further test the effects of PKB on p27 phosphorylation at S10,
T157, and T198, His-p27 was reacted with cellular PKBp473 in
vitro and then immunoblotted and reacted with different anti-
p27 phospho-antibodies (Fig. 3B). While PKB treatment in-
creased p27 reactivity with antibodies raised against pT157 and
pT198, levels of p27pS10 were not increased by PKB. Thus,
while S10 phosphorylation may prime p27 for PKB phosphor-
ylation, S10 does not appear to be a direct PKB site under our
experimental conditions. This is in keeping with the observa-
tion that drug-mediated PKB inhibition also failed to reduce
cellular p27pS10 levels (Fig. 2C).
Loss of phosphorylation at T157 and T198 impairs p27
binding to cyclin D1 and Cdk4 but not to Cdk2. Prior work
showed that the p27 phospho-isoforms present in cyclin D1-
Cdk4 complexes differ from those in cyclin E-Cdk2-bound p27
(12). To further evaluate how p27 phosphorylation may differ
in these respective cyclin-Cdk complexes, Cdk4 and Cdk2 were
immunoprecipitated from asynchronous MCF-7 cells and as-
sociated cellular p27 was immunoblotted with phospho-specific
antibodies (Fig. 4A). While more p27 was present in Cdk4 than
in Cdk2 precipitates, the precipitates were titrated to allow a
comparison of p27 phospho-isoforms in comparable amounts
of total precipitated p27. Cellular p27pT157 and p27pT198
were detected only in Cdk4 precipitates and not in Cdk2 com-
plexes.
To test how the potential for T157 and T198 phosphory-
lation would affect p27 levels and p27-cyclin-Cdk complexes,
YFPp27WT, YFPp27T157A, YFPp27T198A, or YFPp27T157A/
T198A was transfected into MCF-7 cells. Total cyclin D1,
Cdk4, Cdk2, and YFPp27 protein levels are shown (Fig. 4B).
All p27 alleles caused G1 arrest within 48 h of transfection (not
shown). At 12 h posttransfection, cells were not arrested, and
while YFPp27WT and YFPp27T157A levels were similar,
YFPp27T198A and YFPp27T157A/T198A protein levels
were reduced compared to those of YFPp27WT. When
differences in the expression levels of the p27 variants were
VOL. 28, 2008 PKB PROMOTES p27-CYCLIN D1-Cdk4 ASSEMBLY 6465
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taken into account, less YFPp27T157A, YFPp27T198A, and
YFPp27T157A/T198A were detected in cyclin D1 and Cdk4
complexes compared with YFPp27WT (Fig. 4C and D).
Steady-state binding to Cdk2 was similar for all YFPp27
variants compared with YFPp27WT (Fig. 4E). Since
p27T198A and p27T157A/T198A levels were reduced
compared to those of p27WT, the relative binding of these
p27 mutants to Cdk2 was increased, in keeping with the
observations of Kossatz et al. (30). Thus, the absence of
phosphorylation at T157 and T198 reduces p27 association
with cyclin D1 and Cdk4 in cells and may promote Cdk2
binding.
FIG. 2. PI3K inhibition dissociates cyclin D1/Cdk4. (A to B) Lysates were prepared from MCF-7 before and at intervals after the addition of
10 M LY294002 (LY). (A) Left panel, cell cycle proteins were detected by Western blotting; right panel, p27 immune complexes were resolved,
and associated proteins were analyzed by immunoblotting. (B) MCF-7 cells were pulse labeled with BrdU, and cell cycle profiles were analyzed
by flow cytometry. Graphed data represent the average of three independent experiments for each time point. (C) Asynchronous MCF-7 cells were
treated with 10 M LY294002 at time zero and lysed 15, 30, 60, and 240 min later, and immunoblots prepared for total p27 using anti-phospho-p27
antibodies shown. (D) MCF-7 cells were treated with () or without () the MEK inhibitor U0126 (5 M) or LY294002 (10 M) for 24 h. Left
panel, proteins detected by immunoblotting; right panel, p27 was immunoprecipitated, and associated proteins were detected by immunoblotting.
“Ab only” indicates reaction of precipitating antibody with protein A-Sepharose without lysate to control for reactivity of immunoblotting antibody
with heavy or light chain of the antibody used in immunoprecipitation (IP).
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The ability of p27 to promote cyclin D-Cdk4 assembly is
phosphorylation dependent and activated by PKB. We next
tested whether p27 phosphorylation by PKB could affect cyclin
D1-Cdk4 assembly using recombinant proteins in vitro. Bacu-
lovirus-produced cyclin D1 and Cdk4 were mixed with or with-
out the addition of His-p27WT. Their assembly was detected
by immunoprecipitating cyclin D1 or Cdk4, followed by immu-
noblotting of associated proteins. While purified cyclin D1 and
Cdk4 did not form detectable complexes when mixed alone,
the addition of purified His-p27WT increased the amount of
Cdk4 detected in cyclin D1 immunoprecipitates (Fig. 5A), con-
sistent with prior observations (32). To test how PKB pretreat-
ment may influence the effect of added p27 on Cdk4 binding to
cyclin D1 in vitro, p27 was reacted with PKB in vitro and p27
was isolated from these reaction mixtures prior to addition to
cyclin D1 and Cdk4 in vitro. The p27-PKB reaction mixture
was boiled to heat denature the PKB. The heat-precipitated
PKB was removed by centrifugation, the heat-stable p27 was
recovered from the supernatant, and isolated p27 was then
added to cyclin D1-Cdk4. Treatment of His-p27WT with PKB
prior to the assembly reaction markedly increased the ability of
p27 to mediate cyclin D1-Cdk4 assembly (Fig. 5A).
The assembly activity of cellular p27 from either Cdk2 or
cyclin D1 immunoprecipitates was similarly assayed. Cellular
p27 present in immunoprecipitates of Cdk2 or cyclin D1 was
released from these complexes by boiling, and the heat-stable
cellular p27 was recovered. Cellular p27 isolated from Cdk2
was able to mediate the assembly of cyclin D1 and Cdk4 but
did so less effectively than equivalent amounts of p27 isolated
from cellular cyclin D1 complexes (Fig. 5A). When the p27
recovered from Cdk2 precipitates was pretreated with PKB, its
ability to assemble p27-cyclin D1 complexes was increased
(Fig. 5A). These data suggest that the PKB-dependent phos-
phorylation of p27 promotes its assembly function for cyclin
D1 and Cdk4.
To further demonstrate the dependence of p27 assembly
function on phosphorylation, p27 was treated with calf intes-
tinal alkaline phosphatase (CIP) prior to cyclin D1-Cdk4 as-
sembly assays. MCF-7 cells were transfected with Flag-tagged
p27. Immunoprecipitated Flag-p27 was either treated with CIP
or not prior to assembly reactions. p27 was recovered by boil-
ing and reimmunoprecipitating p27 with anti-Flag antibody.
CIP pretreatment markedly reduced the assembly function of
p27 compared with that of the untreated p27 (Fig. 5B). Thus,
the cyclin D1-Cdk4 assembly function of p27 is phosphoryla-
tion dependent.
While the PKB treatment of p27 increased the assembly of
p27-cyclin D1-Cdk4 complexes in vitro, the p27S10A/T157A/
T198A mutant protein showed minimal cyclin D1-Cdk4 assem-
bly. Treatment with PKB did not increase the ability of this
mutant p27 protein to promote cyclin D1-Cdk4 complexes
(Fig. 5C). Taken together, these data indicate that site-specific
phosphorylation of p27 is required to activate its cyclin D1-Cdk
assembly function.
Cyclin D1-Cdk4-p27 assembled in vitro is inactive and re-
quires tyrosine phosphorylation for catalytic activation. Whether
p27-cyclin D1-Cdk complexes can adopt an active conforma-
tion has been a matter of some controversy (1, 2, 9, 26, 32). We
therefore tested whether p27-cyclin D1-Cdk4 assembled in
vitro had catalytic activity toward pRb protein substrate. While
treatment of His-p27WT with PKB prior to the assembly re-
action increased cyclin D1-Cdk4 assembly (Fig. 6A, lane 3),
these complexes were catalytically inactive and failed to phos-
phorylate pRb substrate (Fig. 6B, lane 3). Active cyclin D1-
Cdk4 precipitates from asynchronous cell cultures served as a
positive control for these Cdk4 assays.
We and others recently demonstrated that p27 is phosphor-
ylated by Abl and Src family kinases at tyrosine residues (10,
21). p27 phosphorylation at Y88 prevents its association with
the catalytic cleft of cyclin-bound Cdk2 (21), and Y74 phos-
phorylation of p27 appears to reduce p27-Cdk2 steady-state
binding (10). We therefore tested whether Src treatment would
influence p27-cyclin D1-Cdk4 assembly and/or the activation
of this complex. In contrast to the effect of PKB, pretreat-
ment of p27 with Src (without treatment with PKB) led to
detection of tyrosine phosphorylation of p27 (Fig. 6A, bot-
FIG. 3. Phosphorylation of p27 by PKB in vitro. (A) PKB immu-
noprecipitated from asynchronous WM239 cells was incubated with
His-p27 proteins in the presences of 10 Ci [-32P]ATP. The Coomas-
sie blue stain of the input protein and the radioactivity of His-p27
bands are shown above the graph. The kinase reaction products shown
were run on the same gel, and are all from the same exposure of the
gel. The mean of four independent experiments is graphed. Error bars
indicate the standard deviation. Kinase activity was plotted as a per-
centage of the maximum (% max), setting His-p27WT as 100% max-
imum kinase activity. (B) The PKB kinase reaction was carried out
using His-p27WT as a substrate in the presence of cold ATP in the
presence () or absence () of PKB. Phosphorylation of p27 at S10,
T157, and T198 sites was detected by immunoblotting using phospho-
specific antibodies.
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tom) but did not promote p27 binding to cyclin D1-Cdk4 over
that observed with untreated p27 (Fig. 6A and B, lane 2 versus
lane 4).
We then assayed the effect of Src on cyclin D1-Cdk4-p27
complexes. p27 was pretreated with PKB, isolated, and then
mixed with cyclin D1 and Cdk4 under assembly conditions. Src
treatment led to tyrosine phosphorylation of both input p27
and Cdk4-bound p27 (Fig. 6A, lane 5) and catalytic activation
of p27-cyclin D1-Cdk4 toward pRb (Fig. 6B, lane 5). These
data suggest that while phosphorylation of p27 by PKB pro-
motes assembly of p27-cyclin D1-Cdk4, activation of the com-
plex requires further phosphorylation of p27 at tyrosine sites.
DISCUSSION
Recent data indicate that p27 function is phosphorylation
dependent. The Cdk2-inhibitory function of p27 is attenuated
by tyrosine phosphorylation (10, 21). p27 also binds Cdk4 and
cyclin D1, but whether p27-cyclin D1-Cdk has catalytic activity
has been controversial (1, 2, 9, 26, 32). p27 was shown to
facilitate in vitro assembly of D-type cyclin-Cdks (32), and
double p21/p27 knockout cells show reduced cyclin D-Cdk
complexes, but mechanisms regulating p27-cyclin D-Cdk assem-
bly have been unclear. The observation that cyclin D1-bound p27
and cyclin E-bound p27 have different phospho-isoform patterns
(12) provided early evidence that phosphorylation may regulate
inhibitor and assembly functions of p27. Assembly of cyclin
D1-Cdk4 is mitogen dependent. Despite their active synthesis
in G0, newly formed cyclin D1 and Cdk4 do not assemble in G0
cells (12). Overexpressed cyclin D1 fails to activate Cdk4 in
serum-starved cells, but does activate with serum repletion
(40). Whether mitogen-dependent mechanisms regulate CIP/
KIP phosphorylation to facilitate D-type cyclin-Cdk assembly
has not been clear. The present work indicates that PKB-
dependent phosphorylation of p27 at T157 and T198 appears
to promote p27-cyclin D1-Cdk4 assembly, but further tyrosine
phosphorylation of p27 is required for catalytic activation of
these complexes.
Human p27 is phosphorylated by PKB at T157 (38, 55, 59)
and at T198 in vitro and in cells (19, 20, 42). The present data
provide evidence for coordinate regulation of T157 and T198
phosphorylation in cells. PKB activation, p27 phosphorylation
at T157 and T198 and the appearance of p27-cyclin D1-Cdk4
show close temporal kinetics during G0-to-S progression.
Moreover, the loss of the potential to phosphorylate p27 at
T157 or T198 reduces p27 binding to cellular cyclin D1 and
Cdk4. p27T198A levels were lower than those of either p27WT
or p27T157A, consistent with findings that T198 phosphor-
ylation stabilizes p27 (30, 36). However, the reduction in
p27T198A binding to cyclin D1 was even greater than that
predicted by the reduced p27T198A levels.
Mutation of T198 to alanine attenuated T157 phosphoryla-
tion by PKB in vitro. Phosphorylation at these two sites may be
processive, with phosphorylation at T198 facilitating that at
T157. Phosphorylation of p70S6K by PDK1 and MAPK shows
a similar cooperativity (17). PKB and other AGC kinases,
including SGK1 (24) and RSK1 (20; M. D. Larrea and J. M.
Slingerland, unpublished data) may regulate cooperative p27
phosphorylation at T157 and T198. While p27T157 is not con-
served in mice, p27T198 is (30) and may serve to regulate
cyclin D-Cdk complexes as would murine ACG kinase action
FIG. 4. The potential for T157 and T198 phosphorylation of p27 affects its association with cyclin D1 and Cdk4. (A) Cdk4 (IP Cdk4) and Cdk2
(IP Cdk2) were immunoprecipitated from asynchronous MCF-7 cells. p27 phosphorylated at T157 (p27pT157) and at T198 (p27pT198), total p27,
total Cdk4, and total Cdk2 were detected by immunoblotting. (B to E) MCF-7 cells were transiently transfected with YFPp27 vectors, and cells
were collected 12 h posttransfection. (B) Protein levels were detected by Western blotting. Cyclin D1 (C), Cdk4 (D), and Cdk2 (E) were
immunoprecipitated, and associated YFPp27 was detected by immunoblotting. “Ab only” indicates reaction of precipitating antibody with protein
A-Sepharose without lysate to control for reactivity of immunoblotting antibody with heavy or light chain of the antibody used in immunopre-
cipitation.
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on p21. Coordinate T157 and T198 phosphorylation may per-
mit fine-tuning of p27-cyclin D-Cdk assembly in humans.
p27pT157 and p27pT198 were detected in cellular Cdk4 but
not in Cdk2. It is noteworthy that Kossatz et al. showed that
murine p27T198A binds better to Cdk2 than p27WT (30),
consistent with our finding of a relative increase in p27T198A
binding to cellular Cdk2 compared to p27WT in human cells.
p27 isolated from cellular Cdk2 complexes also assembled
p27-cyclin D1-Cdk4 poorly in vitro compared to p27 from
cyclin D1 complexes. p27 phosphorylation by PKB increased
cyclin D1-Cdk4 assembly in vitro, while CIP-dephosphorylated
p27 and the p27AAA mutant failed to do so. Taken together,
these data suggest that PKB-dependent T157 and T198 phos-
phorylation may promote p27-cyclin D1-Cdk4 assembly. The
shift of p27 from Cdk2 to cyclin D1-Cdk4 complexes observed
in cells upon PKB activation may in part reflect increased p27
phosphorylation at T157 and T198. Since the p27T157 site is
also conserved in p21 (35, 50, 64), PKB-mediated p21 phos-
phorylation may also promote cyclin D-Cdk assembly and
would account for the increased cyclin D1-Cdk4-p21 observed
in PKB-activated cells (35).
In WM35 and other cells, p27pS10 is maximal in G0 and falls
rapidly in early G1 (25). While MAPK can phosphorylate S10
in vitro, MEK inhibition does not reduce p27pS10 in vivo (25).
In Rat1 cells, S10 phosphorylation increases with G0 exit (49),
and hKis and Mirk/dyrkB can phosphorylate p27 at S10 in early
G1 (7, 14). We and others found that p27S10A is a poor
substrate for PKB in vitro (19, 44). While S10 may be a phos-
pho-site for PKB, PKB treatment of recombinant p27 did not
increase p27 reactivity with anti-phospho-p27pS10 antibody
under our experimental conditions. Cellular p27pS10 was max-
imal in G0 when PKB is inactive and fell in early G1 as PKB
activation increased. In addition, PI3K/PKB inhibition rapidly
attenuated cellular p27pT157 and p27pT198 but did not re-
FIG. 5. Cyclin D1-Cdk4 assembly by p27 in vitro is increased by PKB action on p27 and is phosphorylation dependent. (A) Recombinant cyclin
D1 and Cdk4 were incubated without p27 (No p27), with His-p27WT, or with cellular p27 released by boiling from Cdk2 (K2-p27) and cyclin D1
(D1-p27) immune complexes from MCF-7 cells. Where indicated ( or ), p27 was treated with PKB and boiled to remove active PKB prior to
the addition of cyclin D1 and Cdk4 to p27 for the assembly assays. Cyclin D1 was then immunoprecipitated (IP Cyclin D1), and Cdk4 binding was
detected by Western blotting. The bottom panel shows Western blots of the input proteins. (B) p27 was pretreated with () or without () CIP
prior to assembly assays as described above. Input proteins are shown in the bottom panel. (C) Cyclin D1 and Cdk4 were incubated without p27,
with His-p27WT, or with His-p27S10A/T157A/T198A (AAA). Where indicated ( or ), p27 was incubated with PKB, and then p27 was isolated
prior to the addition of cyclin D1 and Cdk4 for the assembly assays. Cdk4 was then immunoprecipitated (IP Cdk4), and Cdk4, cyclin D1, and
His-p27 were detected by Western blotting. The input proteins are indicated.
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duce p27pS10 levels. These data allow that S10 conformation
and indeed prior S10 phosphorylation may facilitate subse-
quent phosphorylation at T157 and T198. S10 phosphoryla-
tion-dependent nuclear export of p27 would augment cytoplas-
mic p27 in early G1, when new synthesis of p27 may be rate
limiting for assembly of newly synthesized cyclin D1-Cdk com-
plexes. While the loss of S10 did not yield any apparent cell
cycle defects in S10A knock-in to p27 null animals (4, 31),
compensation for cell cycle defects is not uncommon in murine
embryogenesis (39).
Prior work has shown that p27-bound cyclin D1-Cdk from
proliferating cells can have catalytic activity (26, 32, 63), while
other data indicated that p27-bound cyclin-D complexes are
inactive (1, 2). The present data together with recent work of
others provides a unifying model for these observations. We
found p27-cyclin D1-Cdk4 complexes formed in vitro were
catalytically inactive. Treatment of assembled p27-cyclin D1-
Cdk4 with Src yielded tyrosine phosphorylation of p27 and
Cdk4 activation. The James et al. group reported that p27 in
inactive p27-cyclin D-Cdk complexes from contact-inhibited
cells is not tyrosine phosphorylated, while p27 is tyrosine phos-
phorylated in cyclin D1-Cdk4 complexes from proliferating
cells, and these have activity toward pRb (26). Tyrosine phos-
phorylation of p27 abrogates its inhibition of cyclin-Cdk2 (10,
21, 28). These data and the present findings suggest a model in
which C-terminal p27 phosphorylation by AGC kinases may
promote p27-cyclin D1-Cdk4 formation or stability, while the
action of Abl or Src family kinases on p27 would be required
for catalytic activation of the assembled complexes. While the
crystal structure of cyclin D1-cdk4-p27 has not been solved,
Y88 of p27 may also lie in the portion of p27 that occludes the
ATP-binding pocket of Cdk4 as it does for Cdk2 and be re-
leased upon Y88 phosphorylation. Thus, multiple signaling
kinases may cooperate to phosphorylate p27 to promote the
assembly and activation of cyclin D1-Cdk4-p27 complexes and
cellular proliferation.
p27 is frequently deregulated in human cancers through
accelerated degradation or mislocalization in the cytoplasm
(56). Increased cytoplasmic p27 is observed in many human
cancers (11). p27pT157 and p27pT198 localize to the cyto-
plasm in certain human cancers (42, 59), and cytoplasmic p27
is uniformly observed in cancers with activated PKB (38, 55,
59). Constitutive mitogenic signaling would activate S10-de-
pendent p27 export, increase cytoplasmic p27, and thus reduce
cyclin E-Cdk2-dependent p27 proteolysis. In addition, T198
phosphorylation may further stabilize p27 (30, 36) in p27-cyclin
D-Cdk complexes, protecting p27 from KPC-mediated degra-
dation, a proteolytic mechanism that acts only on non-Cdk-
bound p27 in the cytoplasm (22, 27). Stable cytoplasmic p27
may acquire novel functions to promote cell motility and tumor
metastasis (5, 15, 34, 41, 45, 61). In the current model, onco-
genic PKB and Src family activation would cooperate to reg-
ulate T157, T198, and tyrosine phosphorylation to stabilize
cytoplasmic p27, promote cyclin D1-Cdk assembly and activa-
tion, and the acquisition of prooncogenic p27 action during
tumorigenesis. These data provide a rationale for the com-
bined use of PI3K/PKB and Src family inhibitors to restore p27
function in human cancers.
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